Bicara Therapeutics Inc’s recent filing unveils that its Director RA CAPITAL MANAGEMENT, L.P. acquired Company’s shares for reported $32.99 million on Sep 16 ’24. In the deal valued at $18.00 per share,1,833,000 shares were bought. As a result of this transaction, RA CAPITAL MANAGEMENT, L.P. now holds 4,303,418 shares worth roughly $61.88 million.
Then, Flynn James E bought 70,000 shares, generating $1,260,000 in total proceeds. Upon buying the shares at $18.00, the Possible Members of 10% Group now owns 897,587 shares.
H.C. Wainwright initiated its Bicara Therapeutics Inc [BCAX] rating to a Buy in a research note published on December 06, 2024; the price target was $42. A number of analysts have revised their coverage, including Rodman & Renshaw’s analysts, who began to cover the stock in early November with a ‘”a Buy”‘ rating. TD Cowen began covering BCAX with “Buy” recommendation on October 08, 2024. Stifel started covering the stock on October 08, 2024. It rated BCAX as “a Buy”.
Price Performance Review of BCAX
On Friday, Bicara Therapeutics Inc [NASDAQ:BCAX] saw its stock fall -5.70% to $14.38. Over the last five days, the stock has lost -15.04%. Bicara Therapeutics Inc shares have fallen nearly -17.45% since the year began.
Levels Of Support And Resistance For BCAX Stock
The 24-hour chart illustrates a support level at 13.77, which if violated will result in even more drops to 13.15. On the upside, there is a resistance level at 15.36. A further resistance level may holdings at 16.33. The Relative Strength Index (RSI) on the 14-day chart is 31.42, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.91, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.55%. Stochastics %K at 2.93% indicates the stock is a buying.
How much short interest is there in Bicara Therapeutics Inc?
A steep rise in short interest was recorded in Bicara Therapeutics Inc stocks on 2024-12-13, growing by 0.96 million shares to a total of 3.03 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 2.07 million shares. There was a rise of 31.56%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 08, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Overweight”‘ rating along with a $35 price target.
